CN Patent
CN103739581B — C-芳基葡萄糖苷sglt2抑制剂
Assigned to China Pharmaceutical University · Expires 2016-11-23 · 9y expired
What this patent protects
本发明涉及与糖尿病相关的药物领域,具体涉及含多芳基葡萄糖苷结构的2型钠‑葡萄糖转运蛋白(SGLT2)的抑制剂、其制备方法、以及该类化合物为活性成分的药物组合物以及它们在制备抗糖尿病药物中应用。
USPTO Abstract
本发明涉及与糖尿病相关的药物领域,具体涉及含多芳基葡萄糖苷结构的2型钠‑葡萄糖转运蛋白(SGLT2)的抑制剂、其制备方法、以及该类化合物为活性成分的药物组合物以及它们在制备抗糖尿病药物中应用。
Drugs covered by this patent
- Farxiga (DAPAGLIFLOZIN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.